Figure 1.
Cell culture treatment protocol. (A) Single agonist protocol: after 24 h in serum-free media, HMSMC were treated with PGF2α for 6 h (0.1, 1, or 10 μM), IL-1β for 6 or 12 h (1 or 5 ng/mL), or IL-6 for 12 h (5 or 15 ng/mL), in order to demonstrate their effects alone and determine optimal concentrations for subsequent treatments. (B) Double agonist protocol: after 24 h in serum-free media, HMSMC were treated with (i) IL-1β for 24 h (5 ng/mL), HBSS wash, then PGF2α for 6 h (10 μM) or (ii) PGF2α for 24 h (10 μM), HBSS wash, then IL-1β for 6 h (5 ng/mL).